Antibody Fragment Production Breakthrough with 2nd Generation EBA
Richter-Helm BioLogics GmbH & Co. KG announced a technological breakthrough in the field of purification of antibody fragments from an E. coli Expression system. Richter-Helm BioLogics has finalized the downstream process for Phase III clinical trial material using 2nd Generation Expanded Bed Adsorption (EBA) technology developed by the Danish biotech company Upfront Chromatography A/S.
Having conducted a series of tests, Richter-Helm has discovered significant advantages of 2nd Generation EBA over the latest, alternative chromatographic methods. A 60% increase in yield was observed using direct capture. The simplified process is less likely to cause processing problems. The processing time to take product from homogenate to clarified, partially purified material was reduced to one working day, decreasing the possibility of product degradation. The volume of buffers required to perform clarification and capture was reduced significantly, effecting cost of manufacture. According to the company, Upfront’s innovation lay in the usage of higher density adsorbents and the proprietary design of an operational system which provides increased flow rates and is free from clogging and channel formation.
Selection of proprietary mixed mode ligand chemistry enables efficient control of the capture and release of target molecules by simple changes of pH, which can be readily implemented in large-scale production facilities and maintain biological activity of the product. Mixed mode ligands are selected for their suitability for industrial processing, in particular their stability during high temperature cleaning with 1M NaOH, low toxicity, and very low leakage from adsorbent.
Most read news
Topics
Organizations
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Lab901 and Biofortuna to collaborate on automated PCR Dx for HLA and Coeliac disease
Mode of action of the vaccine adjuvant flagellin in fusion proteins has been clarified
Alternative methods replace animal experiments: 20 years successful work by ZEBET within BfR - ZEBET celebrates its anniversary with an international symposium at BfR in Berlin
Imaging the smallest atoms provides insights into an enzyme's unusual biochemistry - This could help in the design of enzymes for the chemical industry
Clever biomolecular labelling enables identification of immune cells - New strategy for labelling peptides
Method aims to predict allergenic potency of chemicals
QIAGEN partners with sequencing provider
Making cars and airplanes cheaper, safer and more efficient - DFG funds 2 major instruments to test components made of fiber-reinforced composites
Enterome and Nestlé Health Science launch new diagnostics company
New wheat diversity discovery could provide an urgently-needed solution to global food security - Newly-discovered diversity in the wheat genome could offer vital new opportunities to improve and ‘climate-proof’ one of the world’s most important staple crops
Hidden properties of solids